← Leaderboards
Bradley T. Keller
Accuronix Therapeutics, Inc.
$1,016,958
Attributed
$2,033,915
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2021–22$2M$1.5M$1M$500K$0
'21
'22
Funding mix
By agency
NIH$2,033,915 · 1
By mechanism
R42$2,033,915 · 1
Top collaborators
- William G Hawkins2 shared
Others in their field
Other Emerging Leaders on “Antineoplastic Agents”
- Leonard Freedman · Leidos Biomedical Research, Inc.$243,278,693
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,166,869
- Leonard Freedmand · Leidos Biomedical Research, Inc.$54,796,285
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$29,626,259
- James Jeffrey Sahn · 4e Therapeutics Inc.$7,126,294
- Jeffrey H. Price · Vala Sciences, Inc.$5,562,326
Research focus
Antineoplastic AgentsAntiporterAqueousBaseBiological AvailabilityBody WeightCancer CellCancer Cell GrowthCancer EtiologyCancer ModelCancer PatientCancer TypeCanis FamiliarisCardiacCardiovascular SystemCell DeathCellsCessation Of LifeChemical StabilityClinical TrialsCommercial ApplicationCystineCytotoxicityAnemia